Looking at this filing, I need to identify key financial figures and disclosures from the substantive content. The filing is a 10-Q for BioMarin Pharmaceutical Inc. for the quarterly period ended September 30, 2026. Let me assess the substantive disclosure content - the filing text provided is largely cover page material, forward-looking statement boilerplate, risk factor summaries, and cautionary language. There is mention of the Amicus Acquisition as a notable substantive disclosure item, and share count data. Let me check if the substantive content meets the 150-word threshold. Substantive disclosures present: 193,694,734 shares outstanding as of October 26, 2026; references to the Amicus Acquisition (anticipated benefits, cost savings, material expenses); quarterly period ended September 30, 2026; large accelerated filer status. The risk factors summary referencing the Amicus Acquisition constitutes substantive content beyond boilerplate. This clears the 150-word threshold for substantive disclosure. The ticker shown on the cover page is BMRN on The Nasdaq Global Select Market. I'll write "NASDAQ:BMRN."

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the Securities and Exchange Commission on November 3, 2026, disclosing share count, filer status, and risk factors including those tied to the Amicus Acquisition.

Key Highlights

  • Shares outstanding: 193,694,734 shares of common stock, par value $0.001, were outstanding as of October 26, 2026, according to the filing.
  • Filer classification: BioMarin is classified as a large accelerated filer, as indicated on the cover page of the report.
  • Amicus Acquisition risks flagged: The company disclosed that it "may not realize the anticipated benefits from the Amicus Acquisition or accurately forecast the future performance of the combined company."
  • Material acquisition expenses: The filing states the company "has incurred and expects to incur material expenses related to the Amicus Acquisition."
  • Cost savings uncertainty: BioMarin disclosed it "may not realize the anticipated cost savings from the Amicus Acquisition."
  • Exchange listing: Common stock is registered on The Nasdaq Global Select Market under trading symbol BMRN.

BioMarin's September 2026 Quarterly Filing and Amicus Acquisition Disclosures

BioMarin Pharmaceutical Inc., headquartered at 770 Lindaro Street, San Rafael, California 94901, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing confirms the company is incorporated in Delaware and carries I.R.S. Employer Identification Number 68-0397820. The report indicates BioMarin had 193,694,734 shares of common stock outstanding as of October 26, 2026, and that the company qualifies as a large accelerated filer under the Exchange Act.

A notable feature of this quarterly report is the disclosure of risks specifically related to what the filing identifies as "the Amicus Acquisition." According to the filing, the company may not realize anticipated benefits from the acquisition and may not accurately forecast the combined company's future performance. The company also disclosed it has incurred and expects to incur "material expenses" in connection with the transaction, and that anticipated cost savings may not be achieved. These Amicus Acquisition-related risk factors appear as a distinct category alongside standard business, operational, and regulatory risk disclosures.

The filing also includes standard risk disclosures covering product commercialization, regulatory approval, third-party payer coverage and reimbursement, and competitive pressures. BioMarin noted that because "the target patient populations for our products are relatively small," the company must "achieve significant market share and maintain high per-patient prices for our products to achieve and maintain profitability," according to the risk factors summary included in the report. The filing contains forward-looking statements subject to the company's cautionary language and risk factors described in Part II, Item 1A of the quarterly report and in the Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 26, 2026.

What Was Disclosed

BioMarin filed its Form 10-Q for the quarter ended September 30, 2026, reporting 193,694,734 shares outstanding as of October 26, 2026, large accelerated filer status, and risk factors specifically related to the Amicus Acquisition, including potential failure to realize anticipated benefits, cost savings, and incurrence of material expenses.